Re: hot off the press--targeted therapy in IBC review article
Midwest Alice--EGFR is not routinely looked for (in fact it almost never is in breast cancer, except for in clinical trials)--they are starting to look for it in Triple negatives as it may be a marker for basal breast cancer (a subtype of TN with worse prognosis) and may even being started to be targeted in TN breast cancer.
What I couldn't tell in this article is whether EGFR was positive mainly in the her2-IBCs or also in her2+ IBCs.
|